Shortly after canning its lead and acquiring the NK cell company Cytosen, Kiadis flips part of the tech to Sanofi.
Merck & Co might have got off to a slow start, but now hopes to make up for lost time with multiple projects.
Silence has received an important validation, but making progress could be tough.
Cytomx’s bispecific Probody approach attracts Astellas in a deal with a seemingly high up-front payment.
Using drugs that can cause or exacerbate lung infections to treat the novel coronavirus – what could go wrong?
The deal between Sangamo and Biogen marks another endorsement of a gene-editing technology that many had written off years ago.